©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Hepatol. Jul 18, 2015; 7(14): 1828-1833
Published online Jul 18, 2015. doi: 10.4254/wjh.v7.i14.1828
Published online Jul 18, 2015. doi: 10.4254/wjh.v7.i14.1828
Voriconazole and the liver
Romeo-Gabriel Mihăilă, Faculty of Medicine, Lucian Blaga University of Sibiu, 550169 Sibiu, Romania
Author contributions: Mihăilă RG solely contributed to this manuscript.
Conflict-of-interest statement: The author has no conflict-of-interest related to this article.
Correspondence to: Romeo-Gabriel Mihăilă, MD, PhD, Faculty of Medicine, Lucian Blaga University of Sibiu, Str Lucian Blaga, 2A, 550169 Sibiu, Romania. romeomihaila@yahoo.com
Telephone: +40-269-215050 Fax: +40-269-218365
Received: January 21, 2015
Peer-review started: January 21, 2015
First decision: February 7, 2015
Revised: February 21, 2015
Accepted: April 10, 2015
Article in press: April 14, 2015
Published online: July 18, 2015
Processing time: 184 Days and 15.8 Hours
Peer-review started: January 21, 2015
First decision: February 7, 2015
Revised: February 21, 2015
Accepted: April 10, 2015
Article in press: April 14, 2015
Published online: July 18, 2015
Processing time: 184 Days and 15.8 Hours
Core Tip
Core tip: Voriconazole is an azole useful for the prophylaxis and the treatment of aspergillosis and other fungal infections in immunosuppressed subjects. Its administration in therapeutic doses lead to extremely varied serum levels from patient to patient and even to the same patient. It is recommended to maintain the serum concentrations of voriconazole between 1.5 and 4 μg/mL. At lower values its efficacy decreases and at higher values the risk of neurological toxicity increases. Even at these concentrations it is not excluded the possible appearance of a variety of toxic effects, including on the liver, manifested by cholestasis, hepatocytolisis, or their combination.